Prisys Biotech, a leading contract research organization (CRO) that specializes in in vivo experiments using non-human primates (NHPs) and other species, participated in the annual meeting of the Japanese Society of Toxicology (JSOT) in 2023, and displayed its innovative NHP model platform.
The JSOT annual meeting, held in Yokohama from June 19 to 21, 2023, was a major event for toxicologists and related researchers from Japan and abroad. The meeting featured keynote lectures, symposia, workshops, poster sessions, and exhibitions on various topics related to toxicology.
Prisys Biotech was one of the exhibitors at the meeting, showcasing its NHP model platform that provides "one-stop" solutions for a variety of animal experiments, utilizing its unique modeling techniques in NHPs and other species. Prisys Biotech's NHP model platform offers comprehensive solutions for drug development, from proof-of-concept to clinical applications, and additional support services such as project management, data analysis, and regulatory consulting.
Prisys Biotech's NHP model platform covers a wide range of disease areas, such as neurology, immunology, infectious diseases, metabolic diseases, and respiratory diseases. Prisys Biotech has developed several innovative NHP models and specialty technologies with a growing pipeline, such as deep learning-based 3D behavioral quantification system¹, aerodynamic laboratories for pulmonary exposure and clinical measurements¹, and adeno-associated virus (AAV) gene therapy.
Prisys Biotech also offers multiple cooperative development options for successful R&D collaborations with customers. Joint development option allows customers to retain ownership of intellectual property. Prisys Biotech's long-term research agreements provide specialized support for developing new products in cancer and gynecology fields.
At the JSOT annual meeting, Prisys Biotech attracted the attention of many attendees with its NHP model platform. Prisys Biotech representatives demonstrated the features and advantages of their platform and answered questions from interested researchers. Prisys Biotech also exchanged views and ideas with other exhibitors and participants on the latest developments and trends in toxicology.
Prisys Biotech's participation in the JSOT annual meeting was a successful showcase of its NHP model platform and a valuable opportunity to network with potential partners and customers. Prisys Biotech aims to be the leading innovator in NHP disease modeling and the capstone platform with global innovation-centered collaborations, delivering more translational science and transformational technologies for new medicine.
